Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Melanoma 1Hemangiosarcoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cisplatin 66Paclitaxel 43Radiotherapy 39Carboplatin 29Fluorouracil 27Drug Therapy 20Irinotecan 16toripalimab 15pembrolizumab 15tislelizumab 14camrelizumab 13sintilimab 12Radiotherapy, Intensity-Modulated 11Albumin-Bound Paclitaxel 11S 1 (combination) 10Capecitabine 10130-nm albumin-bound paclitaxel 10apatinib 9Radiation 9Oxaliplatin 9Neoadjuvant Therapy 9Esophagectomy 9Docetaxel 9nimotuzumab 8TP protocol 8Cetuximab 8anlotinib 7Nivolumab 7nedaplatin 6Taxes 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Esophageal Squamous Cell Carcinoma × SGN-LIV1A × Clear all
NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Seagen Inc.

Phase 2 Terminated
205 enrolled 54 charts
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡